camostat has been researched along with Colitis, Ulcerative in 1 studies
camostat : A benzoate ester resulting from the formal condensation of the carboxy group of 4-guanidinobenzoic acid with the hydroxy group of 2-(dimethylamino)-2-oxoethyl (4-hydroxyphenyl)acetate. It is a potent inhibitor of the human transmembrane protease serine 2 (TMPRSS2) and its mesylate salt is currently under investigation for its effectiveness in COVID-19 patients.
Colitis, Ulcerative: Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Senda, S | 1 |
| Fujiyama, Y | 1 |
| Bamba, T | 1 |
| Hosoda, S | 1 |
1 other study available for camostat and Colitis, Ulcerative
| Article | Year |
|---|---|
Treatment of ulcerative colitis with camostat mesilate, a serine protease inhibitor.
Topics: Adult; Colitis, Ulcerative; Esters; Gabexate; Guanidines; Humans; Male; Serine Proteinase Inhibitors | 1993 |